Novavax annual operating margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Novavax's operating margin was 40.30% for fiscal 2025.
View full Novavax company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 40.30% | +76.79 pp |
| 2024 | 2024-12-31 | −36.49% | +21.10 pp |
| 2023 | 2023-12-31 | −57.59% | −25.06 pp |
| 2022 | 2022-12-31 | −32.53% | +114.60 pp |
| 2021 | 2021-12-31 | −147.13% | −59.51 pp |
| 2020 | 2020-12-31 | −87.62% | +558.51 pp |
| 2019 | 2019-12-31 | −646.13% | −138.90 pp |
| 2018 | 2018-12-31 | −507.23% | +43.55 pp |
| 2017 | 2017-12-31 | −550.78% | +1202.06 pp |
| 2016 | 2016-12-31 | −1,752.84% | −1319.08 pp |
| 2015 | 2015-12-31 | −433.75% | −160.78 pp |
| 2014 | 2014-12-31 | −272.97% | −22.27 pp |
| 2013 | 2013-12-31 | −250.70% | −116.32 pp |
| 2012 | 2012-12-31 | −134.38% | +12.54 pp |
| 2011 | 2011-12-31 | −146.92% | +11075.82 pp |
| 2010 | 2010-12-31 | −11,222.74% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −96.84% | −139.09 pp |
| Q1 2026 | 2026-03-31 | −11.06% | −88.39 pp |
| Q4 2025 | 2025-12-31 | 9.67% | +158.10 pp |
| Q3 2025 | 2025-09-30 | −252.70% | −94.13 pp |
| Q2 2025 | 2025-06-30 | 42.25% | +3.50 pp |
| Q1 2025 | 2025-03-31 | 77.33% | +231.64 pp |
| Q4 2024 | 2024-12-31 | −148.43% | −85.42 pp |
| Q3 2024 | 2024-09-30 | −158.58% | −91.39 pp |
| Q2 2024 | 2024-06-30 | 38.75% | +25.68 pp |
| Q1 2024 | 2024-03-31 | −154.31% | +232.05 pp |
| Q4 2023 | 2023-12-31 | −63.01% | +5.23 pp |
| Q3 2023 | 2023-09-30 | −67.19% | −49.87 pp |
| Q2 2023 | 2023-06-30 | 13.07% | +272.83 pp |
| Q1 2023 | 2023-03-31 | −386.37% | −416.10 pp |
| Q4 2022 | 2022-12-31 | −68.24% | +303.04 pp |
| Q3 2022 | 2022-09-30 | −17.31% | +154.42 pp |
| Q2 2022 | 2022-06-30 | −259.76% | −143.72 pp |
| Q1 2022 | 2022-03-31 | 29.73% | +76.38 pp |
| Q4 2021 | 2021-12-31 | −371.27% | −305.89 pp |
| Q3 2021 | 2021-09-30 | −171.74% | −48.23 pp |
| Q2 2021 | 2021-06-30 | −116.04% | −68.13 pp |
| Q1 2021 | 2021-03-31 | −46.65% | +631.38 pp |
| Q4 2020 | 2020-12-31 | −65.38% | +260.22 pp |
| Q3 2020 | 2020-09-30 | −123.51% | +474.30 pp |
| Q2 2020 | 2020-06-30 | −47.91% | +1044.31 pp |
| Q1 2020 | 2020-03-31 | −678.03% | +332.09 pp |
| Q4 2019 | 2019-12-31 | −325.60% | +433.53 pp |
| Q3 2019 | 2019-09-30 | −597.81% | −56.11 pp |
| Q2 2019 | 2019-06-30 | −1,092.23% | −702.43 pp |
| Q1 2019 | 2019-03-31 | −1,010.12% | −559.35 pp |
| Q4 2018 | 2018-12-31 | −759.13% | −300.19 pp |
| Q3 2018 | 2018-09-30 | −541.69% | −43.27 pp |
| Q2 2018 | 2018-06-30 | −389.80% | +226.23 pp |
| Q1 2018 | 2018-03-31 | −450.77% | +268.00 pp |
| Q4 2017 | 2017-12-31 | −458.94% | +542.08 pp |
| Q3 2017 | 2017-09-30 | −498.42% | +1460.97 pp |
| Q2 2017 | 2017-06-30 | −616.03% | +2437.78 pp |
| Q1 2017 | 2017-03-31 | −718.77% | +1065.54 pp |
| Q4 2016 | 2016-12-31 | −1,001.02% | +347.29 pp |
| Q3 2016 | 2016-09-30 | −1,959.39% | −1450.60 pp |
| Q2 2016 | 2016-06-30 | −3,053.81% | −2905.05 pp |
| Q1 2016 | 2016-03-31 | −1,784.31% | −1538.15 pp |
| Q4 2015 | 2015-12-31 | −1,348.31% | −877.37 pp |
| Q3 2015 | 2015-09-30 | −508.80% | −267.88 pp |
| Q2 2015 | 2015-06-30 | −148.76% | +67.38 pp |
| Q1 2015 | 2015-03-31 | −246.16% | −53.38 pp |
| Q4 2014 | 2014-12-31 | −470.94% | −308.04 pp |
| Q3 2014 | 2014-09-30 | −240.92% | +77.26 pp |
| Q2 2014 | 2014-06-30 | −216.14% | +149.14 pp |
| Q1 2014 | 2014-03-31 | −192.78% | +68.25 pp |
| Q4 2013 | 2013-12-31 | −162.90% | +45.03 pp |
| Q3 2013 | 2013-09-30 | −318.18% | −199.38 pp |
| Q2 2013 | 2013-06-30 | −365.28% | −282.85 pp |
| Q1 2013 | 2013-03-31 | −261.02% | −100.17 pp |
| Q4 2012 | 2012-12-31 | −207.93% | −128.69 pp |
| Q3 2012 | 2012-09-30 | −118.80% | — |
| Q2 2012 | 2012-06-30 | −82.43% | — |
| Q1 2012 | 2012-03-31 | −160.86% | — |
| Q3 2011 | 2011-09-30 | −79.23% | — |
Over the last five reported fiscal years, Novavax's operating margin increased from −87.62% to 40.30%, a change of +127.92 percentage points. The latest reported quarter, Q2 2026, shows −96.84%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novavax filings at SEC.gov ↗